D. E. Shaw & Co., Inc. - FATE THERAPEUTICS INC ownership

FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 253 filers reported holding FATE THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.41 and the average weighting 0.4%.

Quarter-by-quarter ownership
D. E. Shaw & Co., Inc. ownership history of FATE THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$9,988,728
-54.4%
4,711,664
+2.4%
0.01%
-54.5%
Q2 2023$21,893,330
+29.5%
4,599,439
+55.1%
0.02%
+22.2%
Q1 2023$16,901,880
+549.5%
2,965,242
+1049.7%
0.02%
+500.0%
Q4 2022$2,602,443
+34.2%
257,923
+415.8%
0.00%
+50.0%
Q1 2022$1,939,000
+83.6%
50,000
+180.6%
0.00%
+100.0%
Q3 2021$1,056,000
-85.4%
17,821
-78.7%
0.00%
-83.3%
Q2 2021$7,251,000
-71.3%
83,548
-72.7%
0.01%
-75.0%
Q1 2021$25,249,000
-29.9%
306,238
-22.7%
0.02%
-25.0%
Q4 2020$36,022,000
+71.2%
396,157
-24.7%
0.03%
+45.5%
Q3 2020$21,037,000
+36.0%
526,327
+16.7%
0.02%
+22.2%
Q2 2020$15,472,000
+65.4%
450,960
+7.1%
0.02%
+20.0%
Q1 2020$9,355,000
+350.0%
421,201
+296.4%
0.02%
+650.0%
Q4 2019$2,079,000
+670.0%
106,252
+697.6%
0.00%
Q2 2019$270,000
-24.8%
13,322
-63.8%
0.00%
Q1 2018$359,00036,7960.00%
Other shareholders
FATE THERAPEUTICS INC shareholders Q1 2022
NameSharesValueWeighting ↓
JOHNSON & JOHNSON 3,379,064$131,006,00024.77%
Redmile Group, LLC 12,957,222$502,351,00015.68%
Grosvenor Holdings, L.L.C. 1,037,256$40,214,0007.85%
Casdin Capital, LLC 3,400,000$131,818,0005.91%
Ally Bridge Group (NY) LLC 181,500$7,037,0005.22%
DAFNA Capital Management LLC 500,930$19,421,0005.06%
Deep Track Capital, LP 2,000,000$77,540,0004.97%
Artal Group S.A. 2,000,000$77,540,0003.25%
Tri Locum Partners LP 190,345$7,380,0002.88%
ARK Investment Management 10,988,182$426,012,0001.78%
View complete list of FATE THERAPEUTICS INC shareholders